[en] 41 patients with active rheumatoid arthritis entered a placebo-controlled double-blind randomised study in which 21 received slow intravenous injections (given in fractions over 10 min) of thymopentin (TP·5) 50 mg 3 times a week for 3 consecutive weeks and 20 received placebo in the same way. After 3 weeks of treatment the TP-5 group showed improvement (p
Disciplines :
Rheumatology
Author, co-author :
Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Goldstein (1971) Thymin a thymic polypeptide causing the neuromuscular block of myasthenia gravis. Ann NY Acad Sci 183:230-240.
Schlesinger, Goldstein (1975) The amino acid sequence ofthymopoietin II. Cell 5:361-365.
Goldstein, Schneid, Boyse, Schlesinger, van Wauve (1979) A synthetic pentapeptide with biological activity characteristics of the thymic hormone thymopoietin. Science 204:1309-1310.
Basch, Goldstein (1975) Antigenic and functional evidence for the in vitro inductive activity of thymopoietin on thymocyte precursors. Ann NY Acad Sci 249:290-297.
Scheid, Goldstein, Boyse (1978) The generation and regulation of lymphocyte population. Journal of Experimental Medicine 148:1727-1743.
Scheid, Goldstein, Boyse (1975) Differentiation of T cells in nude mice. Science 190:1211-1213.
Lau, Freestone, Goldstein (1980) Effect of thymopoietin pentapeptide on autoimmunity I. TP-5 suppression of induced erythrocyte autoantibodies in C3H mice. J Immunol 125:1634-1638.
Weksler, Innes, Goldstein (1978) Immunological studies of aging IV. The contribution of thymic involution to the immune deficiencies of aging mice and reversal with thymopoietin 32-36. J Exp Med 148:996-1006.
Sunshine, Basch, Goffrey, Cohen, Goldstein, Hadden (1978) Thymopoietin enhances the allogenic response and cyclic GMP levels of mouse peripheral thymus-derived lymphocytes. J Immunol 120:1594-1599.
Lau, Goldstein (1980) Functional effects of TP-5 on cytotoxic lymphocyte precursor units (CLP.U) I. Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulations. J Immunol 124:1861-1865.
Lau, Wang, Goldstein (1982) Effects of thymopoietin pentapeptide on experimental tumors I. TP-5 relieves immunosuppression in tumor-bearing mice. Cell Immunol 66:217-232.
Duchateau, Delespesse, Bolla (1983) Phase variation in the modulation of the human immune response. Immunol Today 4:213-214.
Tischio, Patrick, Weintraub, Chasing, Goldstein (1979) Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma. Int J Pept Prot Res 14:479-484.
DiPerri, Laghi Pasini, Auteri (1980) Immunokinetics of a single dose of thymopoietin pentapeptide. Immunopharmacology and Immunotoxicology 2:567-572.
Bolla, Duchateau, Delespesse, Servais Clinical-pharmacological evidence for the immunomodulatory property of thymopentin in elderly volunteers, Bioscience Ediprint Inc, Geneva, Proceedings of the 1st World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, Venice (in press); 1984.
Audhya, Goldstein (1983) Comparative efficacy of various routes of administration of thymopentin (TP-5) with considerations of degradative mechanisms. Int J Pept Prot Res 22:187-193.
Audhya, Goldstein (1983) Thymopentin (TP-5) potency in vivo is enhanced by slow infusion. Int J Pept Prot Res 22:568-572.
Janossy, Duke, Paulter, Panayi, Bofill, Goldstein (1981) Rheumatoid arthritis- a disease of T lymphocyte/macrophage immunoregulation. Lancet 2:839-842.
Veys, Hermans, Schindler (1982) Evaluation of T cell subsets with monoclonal antibodies in patients with rheumatoid arthritis. J Rheumatol 9:25-29.
Veys, Huskisson, Rosenthal (1982) Clinical responses to therapy with thymopentin (TP-5) in rheumatoid arthritis. Ann Rheum Dis 41:441-443.
Rosenthal, Huskisson, Veys, Vischer (1981) Thymopentin bei der Behandlung der chronischen Polyarthritis. Verth Dtsch Ges Rheumatol 7:400-443.
Horwith, Glynn, Barada (1980) Effects of thymopoietin 32-36 (TP-5) in rheumatoid arthritis: A preliminary report. Immunoregulation and autoimmunity. , Rs Krakauer, Mk Cathcart, Elsevier/North Holland, Amsterdam; 231-240.
Weaver, Churchill, Jacobs (1984) Treatment of refractory rheumatoid arthritis with thymopoietin pentapeptide Abstract. Arthritis Rheum , (suppl); 27:B46.
Veys, Mielants, Verbruggen (1984) Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis A compilation of several short- and long-term clinical studies. J Rheumatol 11:462-466.
Sharpe (1976) HCG-induced decrease in availability of rat testis receptors. Nature(Lond) 264:644-646.
Franchimont, Hauwaert, Bolla Controlled open clinical study with 'Immunox' (TP-5) in the treatment of active rheumatoid arthritis, Documentation CILAG Ltd, Schaffhausen, Switzerland, TPH 01579; 1983.
Cooperating Clinic Committee of American Rheumatism Association Arthritis Rheum 1976, 8:302-310.
Ritchie, Boyle, McInnes (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Quart J Med 37:393-406.
Huskisson (1974) Measurement of pain. Lancet 2:1127-1131.
Umbenhauer (1981) Is the ability to detect drug effect in rheumatic diseases increased by measuring more clinical parameters?. Controversies in the clinical evaluation of analgesic-anti-inflammatory-antirheumatic drugs. , He Paulus, Ge Ehrlich, E. Lindenlaub, F. K. Schattaeur, Stuttgart; 193-202.
